Skip to main content
SpringerLink
Log in

Levodopa reverses gait asymmetries related to anhedonia and magical ideation

  • ORIGINAL PAPER
  • Published:
European Archives of Psychiatry and Clinical Neuroscience Aims and scope Submit manuscript

Abstract

Animals and men turn preferentially away from the hemisphere with the more active dopamine (DA) system. Consistent with the idea of a right–hemispheric hyperdopaminergia in schizophrenia, a leftsided turning bias was described for unmedicated psychotic patients. We investigated the modulating role of DA and schizophrenia–like thought on whole–body turns in a controlled double–blind study. The number of veers to either side when walking blindfolded straight ahead (20 meter) was assessed in 40 healthy righthanded men (20 men received levodopa, the remaining participants placebo). Side preferences were analyzed in terms of individuals’ positive (Magical Ideation, MI) and negative (Physical Anhedonia, PhysAn) schizotypal features. In the placebo group, increasing MI scores were related to increasing left–sided veering and increasing PhysAn scores were related to increasing right–sided veering. In the levodopa group, this relationship between preferred veering side and type of schizotypy was reversed. The finding in the placebo group suggests an association between MI and a relative right–hemispheric hyperdopaminergia. Unexpectedly, levodopa did not enhance this veering bias, but reversed it, suggesting that psychosis–protective mechanisms exist in the healthy positive “schizotypic” brain. Also unexpectedly, levodopa made “anhedonics” veer like “magics” after placebo, suggesting that DA agonists suppress negative schizotypal symptoms.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Abi-Dargham A, Gil R, Krystal J, Baldwin RM, Seibyl JP, Bowers M, van Dyck CH, Charney DS, Innis RB, Laruelle M (1998) Increased striatal dopamine transmission in schizophrenia: confirmation in a second cohort. Am J Psychiatry 155:761–767

    CAS  PubMed  Google Scholar 

  2. Andreasen NC (1995) Symptoms, signs, and diagnosis of schizophrenia. Lancet 346:477–481

    Article  CAS  PubMed  Google Scholar 

  3. Angrist B, Peselow E, Rubinstein M, Wolkin A, Rotrosen J (1985) Amphetamine response and relapse risk after depot neuroleptic discontinuation. Psychopharmacology 85:277–283

    Google Scholar 

  4. Barnett KJ, Corballis MC (2002) Ambidexterity and magical ideation. Laterality 7:75–84

    PubMed  Google Scholar 

  5. Bracha HS, Livingston RL, Clothier J, Linington BB, Karson CN (1993) Correlation of severity of psychiatric patients’ delusions with right hemispatial inattention (left-turning behavior). Am J Psychiatry 150:330–332

    CAS  PubMed  Google Scholar 

  6. Bracha HS, Shults C, Glick SD, Kleinman JE (1987) Spontaneous asymmetric circling behavior in hemi-parkinsonism: a human equivalent of the lesioned-circling rodent behavior. Life Sci 40:1127–1130

    Article  CAS  PubMed  Google Scholar 

  7. Bracha HS (1989) Is there a right hemi-hyper-dopaminergic psychosis? Schizophr Res 2:317–324

    Article  CAS  PubMed  Google Scholar 

  8. Brown AS, Gershon S (1993) Dopamine and Depression. J Neural Transm 91:75–109

    CAS  Google Scholar 

  9. Brugger P, Graves RE (1997) Right hemispatial inattention and magical ideation. Eur Arch Psychiatry Clin Neurosci 247:55–57

    CAS  PubMed  Google Scholar 

  10. Campbell JJ (2000) Neuropsychiatric assessment. In: Coffey CE, Cummings JL (eds) Textbook of Geriatric Neuropsychiatry, 2nd ed. American Psychiatric Press, Washington, D.C., pp 109–124

  11. Chapman LJ, Chapman JP, Kwapil TR, Eckblad M, Zinser MC (1994) Putatively psychosis-prone subjects 10 years later. J Abnorm Psychol 103:171–183

    CAS  PubMed  Google Scholar 

  12. Chapman LJ, Chapman JP, Raulin ML (1976) Scales for physical and social anhedonia. J Abnorm Psychol 85:374–382

    Article  CAS  PubMed  Google Scholar 

  13. Chapman LJ, Chapman JP (1987) The measurement of handedness. Brain Cogn 6:175–183

    Article  CAS  PubMed  Google Scholar 

  14. Chapman LJ, Edell WS, Chapman JP (1980) Physical anhedonia, perceptual aberration, and psychosis proneness. Schizophr Bull 6:639–653

    CAS  PubMed  Google Scholar 

  15. Claridge GS, Clark KH, Beech AR (1992) Lateralization of the ‘negative priming’ effect: relationships with schizotypy and with gender. Br J Psychol 83:13–23

    PubMed  Google Scholar 

  16. Daniel DG,Weinberger DR, Jones DW,Zigun JR,Coppola R, Handel S, Bigelow LB, Goldberg TE, Berman KF, Kleinman JE (1991) The effect of amphetamine on regional cerebral blood flow during cognitive activation in schizophrenia. J Neurosci 11:1907–1917

    Google Scholar 

  17. Davidson M, Davis KL (1988) A comparison of plasma homovanillic acid concentration in schizophrenic patients and normal controls. Arch Gen Psychiatry 45:561–563

    CAS  PubMed  Google Scholar 

  18. Davidson M, Keefe RS, Mohs RC, Siever LJ, Losonczy MF, Horvath TB, Davis KL (1987) L-dopa challenge and relapse in schizophrenia. Am J Psychiatry 144:934–938

    CAS  PubMed  Google Scholar 

  19. Davis KL, Kahn RS, Ko G, Davidson M (1991) Dopamine in schizophrenia: a review and reconceptualization. Am J Psychiatry 148:1474–1486

    CAS  PubMed  Google Scholar 

  20. Eckblad M, Chapman LJ (1983) Magical ideation as an indicator of schizotypy. J Consult Clin Psychol 51:215–225

    Article  CAS  PubMed  Google Scholar 

  21. Garety P, Wessely S (1994) The assessment of positive symptoms. In: Barnes TRE, Nelson HE (eds) The Assessment of Psychoses. A Practical Handbook. Chapman and Hall, London, England, pp 21–39

  22. Gasser UE, Jorga K, Crevoisier C, Hovens SE, van Giersbergen PL (1999) COMT inhibition by tolcapone further improves levodopa pharmacokinetics when combined with a dual-release formulation of levodopa/benserazide. A novel principle in the treatment of Parkinson’s disease. Eur Neurol 41:206–211

    Google Scholar 

  23. Glick SD, Ross DA, Hough LB (1982) Lateral asymmetry of neurotransmitters in human brain. Brain Res 234:53–63

    Article  CAS  PubMed  Google Scholar 

  24. Gooding DC, Kwapil TR, Tallent KA (1999) Wisconsin Card Sorting Test deficits in schizotypic individuals. Schizophr Res 40:201–209

    Article  CAS  PubMed  Google Scholar 

  25. Gooding DC, Miller MD, Kwapil TR (2000) Smooth pursuit eye tracking and visual fixation in psychosis-prone individuals. Psychiatry Res 93:41–54

    CAS  PubMed  Google Scholar 

  26. Gray NS, Pickering AD, Snowden RJ, Hemsley DR, Gray JA (2002) The partial reinforcement extinction effect in humans: effects of schizophrenia, schizotypy and low doses of amphetamine. Behav Brain Res 133:333–342

    CAS  PubMed  Google Scholar 

  27. Harvey SA, Nelson E, Haller JW, Early TS (1993) Lateralized attentional abnormality in schizophrenia is correlated with severity of symptoms. Biol Psychiatry 33:93–99

    Article  CAS  PubMed  Google Scholar 

  28. Janowsky DS, Risch C (1979) Amphetamine psychosis and psychotic symptoms. Psychopharmacology 65:73–77

    Google Scholar 

  29. Kalaycioglu C, Nalcaci E, Budanur OE, Genc Y, Cicek M (2000) The effect of familial sinistrality on the relation between schizophrenialike thinking and pseudoneglect. Brain Cogn 44:564–576

    Article  CAS  PubMed  Google Scholar 

  30. Kirrane RM, Siever LJ (2000) New perspective on schizotypal personality disorder. Curr Psychiatry Rep 2:62–66

    CAS  PubMed  Google Scholar 

  31. Klein C, Berg P, Rockstroh B, Andresen B (1999) Topography of the auditory P300 in schizotypal personality. Biol Psychiatry 45:1612–1621

    Article  CAS  PubMed  Google Scholar 

  32. Klein D, Davis J (1969) Diagnosis and Drug Treatment of Psychiatric Disorders. Williams & Wilkins, Baltimore, Md, pp 52–138

  33. Kopp B, Wolff M, Hruska C, Reischies FM (2002) Brain mechanisms of visual encoding and working memory in psychometrically identified schizotypal individuals and after acute administration of haloperidol. Psychophysiology 39:459–472

    Article  PubMed  Google Scholar 

  34. Kumari V, Cotter PA, Mulligan OF, Checkley SA, Gray NS, Hemsley DR, Thornton JC, Corr PJ, Toone BK, Gray JA (1999) Effects of d-amphetamine and haloperidol on latent inhibition in healthy male volunteers. Psychopharmacology 13:398–405

    CAS  Google Scholar 

  35. Kwapil T, Miller M, Zinser M, Chapman J, Chapman L (1997) Magical Ideation and social anhedonia as predictors of psychosis proneness: a partial replication. J Abnorm Psychol 106:491–495

    Article  CAS  PubMed  Google Scholar 

  36. Laruelle M, Abi-Dargham A (1999) Dopamine as the wind of the psychotic fire: new evidence from brain imaging studies. J Psychopharmacol 13:358–371

    CAS  PubMed  Google Scholar 

  37. Levine J, Martine T, Feraro R, Kimhi R, Bracha HS (1997) Medicated chronic schizophrenic patients do not demonstrate left turning asymmetry. Neuropsychobiology 36:22–24

    CAS  PubMed  Google Scholar 

  38. Loas G, Boyer P, Legrand A (1999) Anhedonia in the deficit syndrome of schizophrenia. Psychopathology 32:207–219

    Article  CAS  PubMed  Google Scholar 

  39. Maruff P, Hay D, Malone V, Currie J (1995) Asymmetries in the covert orienting of visual spatial attention in schizophrenia. Neuropsychologia 33:1205–1223

    Google Scholar 

  40. Matthysse S (1973) Antipsychotic drug actions: a clue to the neuropathology of schizophrenia? Fed Proc 32:200–205

    CAS  PubMed  Google Scholar 

  41. Meehl PE (1962) Schizotaxia, schizotypy, schizophrenia. Am Psychologist 17:827–838

    Google Scholar 

  42. Meyer TD, Hautzinger M (1999) Two year stability of psychosis proneness scales and their relationship to personality disorder traits. J Pers Assess 73:472–488

    Article  CAS  PubMed  Google Scholar 

  43. Mohr C, Bracha HS, Brugger P (2003a) Magical Ideation modulates spatial behavior. J Neuropsychiatry Clin Neurosci 15:168–174

    Google Scholar 

  44. Mohr C, Landis T, Bracha HS, Fathi M, Brugger P (2003b) Human locomotion: levodopa keeps you straight. Neurosci Lett 339:115–118

    Article  CAS  Google Scholar 

  45. Mohr C, Brugger P, Bracha HS, Landis T, Viaud-Delmon I (2004) Human side preferences in three different whole-body movement tasks. Behav Brain Res 151:321–326

    Article  CAS  PubMed  Google Scholar 

  46. Mohr C, Landis T, Sandor PS, Fathi M, Brugger P (in press) Nonstereotyped responding in positive schizotypy after a single dose of levodopa. Neuropsychopharmacology

  47. Park S, Holzman PS, Lenzenweger MF (1995) Individual differences in spatial working memory in relation to schizotypy. J Abnorm Psychol 104:355–363

    CAS  PubMed  Google Scholar 

  48. Pickar D, Labarca R, Linnoila M, Roy A, Hommer D, Everett D, Paul SM (1984) Neuroleptic-induced decrease in plasma homovanillic acid and antipsychotic activity in schizophrenic patients. Science 225:954–957

    CAS  PubMed  Google Scholar 

  49. Pizzagalli D, Lehmann D, Gianotti L, Koenig T, Tanaka H, Wackermann J, Brugger P (2000) Brain electric correlates of strong belief in paranormal phenomena: intracerebral EEG source and regional Omega complexity analyses. Psychiatry Res 100:139–154

    CAS  PubMed  Google Scholar 

  50. Posner MI, Early TS, Reiman E, Pardo PJ, Dhawan M (1988) Asymmetries in hemispheric control of attention in schizophrenia. Arch Gen Psychiatry 45:814–821

    CAS  PubMed  Google Scholar 

  51. Pycock CJ (1983) Experimental model of hemi-Parkinsonism. In: Myslobodsky MS (ed) Hemisyndromes: Psychobiology, Neurology, Psychiatry. Academic Press, New York, USA, pp 69–90

  52. Sarkin AJ, Dionisio DP, Hillix WA, Granholm E (1998) Positive and negative schizotypal symptoms relate to different aspects of crossover reaction time task performance. Psychiatry Res 81:241–249

    Article  CAS  PubMed  Google Scholar 

  53. Scherbarth-Roschmann P, Hautzinger M (1991) Zur psychometrischen Erfassung von Schizotypie: Methodische Überprüfung und erste Validierung von zwei Skalen zur Erfassung von Risikomerkmalen. Z Klin Psychol 20:238–250

    Google Scholar 

  54. Sekine Y, Iyo M, Ouchi Y, Matsunaga T, Tsukada H, Okada H, Yoshikawa E, Futatsubashi M, Takei N, Mori N (2001) Methamphetamine- related psychiatric symptoms and reduced brain dopamine transporters studied with PET. Am J Psychiatry 158:1206–1214

    Article  CAS  PubMed  Google Scholar 

  55. Shaw J, Claridge G, Clark K (2001) Schizotypy and the shift from dextrality: a study of handedness in a large non-clinical sample. Schizophr Res 50:181–189

    Article  CAS  PubMed  Google Scholar 

  56. Shihabuddin L, Buchsbaum MS, Hazlett EA, Silverman J, New A, Brickman AM, Mitropoulou V, Nunn M, Fleischman MB, Tang C, Siever LJ (2001) Striatal size and relative glucose metabolic rate in schizotypal personality disorder and schizophrenia. Arch Gen Psychiatry 58:877–884

    CAS  PubMed  Google Scholar 

  57. Siever LJ, Amin F, Coccaro EF, Bernstein D, Kavoussi RJ, Kalus O, Horvath TB, Warne P, Davidson M, Davis KL (1991) Plasma homovanillic acid in schizotypal personality disorder. Am J Psychiatry 148:1246–1248

    CAS  PubMed  Google Scholar 

  58. Siever LJ, Amin F, Coccaro EF, Trestman R, Silverman J, Horvath TB, Mahon TR, Knott P, Altstiel L, Davidson M, Davis KL (1993) CSF homovanillic acid in schizotypal personality disorder. Am J Psychiatry 150:149–151

    CAS  PubMed  Google Scholar 

  59. Siever LJ, Davis KL (2004) The pathophysiology of schizophrenia disorders: perspectives from the spectrum. Am J Psychiatry 161:398–413

    Article  PubMed  Google Scholar 

  60. Szeszko PR, Bilder RM, Dunlop JA, Walder DJ, Lieberman JA (1999) Longitudinal assessment of methylphenidate effects on oral word production and symptoms in first-episode schizophrenia at acute and stabilized phases. Biol Psychiatry 45:680–686

    Article  CAS  PubMed  Google Scholar 

  61. Taylor KI, Zäch P, Brugger P (2002) Why is magical ideation related to leftward deviation on an implicit line bisection task? Cortex 38:247–252

    PubMed  Google Scholar 

  62. Tomer R, Flor-Henry P (1989) Neuroleptics reverse attention asymmetries in schizophrenic patients. Biol Psychiatry 25:852–860

    Article  CAS  PubMed  Google Scholar 

  63. Tsuang MT, Stone WS, Tarbox SI, Faraone SV (2002) An integration of schizophrenia with schizotypy: identification of schizotaxia and implications for research on treatment and prevention. Schizophr Res 54:169–175

    Article  PubMed  Google Scholar 

  64. Van Os J, Verdoux H, Maurice-Tison S, Gay B, Liraud F, Salamon R, Bourgeois M (1999) Self-reported psychosis-like symptoms and the continuum of psychosis. Soc Psychiatry Psychiatr Epidemiol 34:459–463

    Article  CAS  PubMed  Google Scholar 

  65. Verdoux H, van Os J (2002) Psychotic symptoms in non-clinical populations and the continuum of psychosis. Schizophr Res 54:59–65

    Article  PubMed  Google Scholar 

  66. Williams JH, Wellman NA, Geaney DP, Feldon J, Cowen PJ, Rawlins JN (1997) Haloperidol enhances latent inhibition in visual tasks in healthy people. Psychopharmacology 133:262–268

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Functional Brain Mapping Laboratory , Dept. of Neurology, University Hospital Geneva, Rue Micheli-du-Crest 24, 1211, Geneva 14

    C. Mohr & T. Landis

  2. Dept. of Rehabilitation, University Hospital Geneva, Geneva, Switzerland

    C. Mohr

  3. Dept. of Neurology, University Hospital Zurich, Zurich, Switzerland

    C. Mohr & P. Brugger

  4. Honolulu VA National Centre for PTSD, Honolulu, Hawaii, USA

    H. S. Bracha

  5. Clinical Chemistry Central Laboratory, University Hospital Geneva, Geneva, Switzerland

    M. Fathi

Authors
  1. C. Mohr
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. T. Landis
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. H. S. Bracha
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M. Fathi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. P. Brugger
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to C. Mohr.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mohr, C., Landis, T., Bracha, H.S. et al. Levodopa reverses gait asymmetries related to anhedonia and magical ideation. Eur Arch Psychiatry Clin Neurosci 255, 33–39 (2005). https://doi.org/10.1007/s00406-004-0531-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00406-004-0531-0

Key words

Search

Navigation